Get the Daily Brief
Latest Biotech News
BioMarin buys Amicus: $4.8B deal folds in marketed rare-disease drugs
BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion, gaining two approved therapies for Pompe and Fabry diseases and a late-stage clinical asset. The companies said the purchased...
Takeda’s TYK2 bet pays off – zasocitinib wins two Phase 3 trials
Takeda reported that zasocitinib, the oral TYK2 inhibitor it acquired in a multibillion-dollar deal, met primary and key secondary endpoints in two Phase 3 plaque psoriasis studies. Company...
Lilly’s oral obesity pill ... maintenance trial meets goals
Eli Lilly disclosed positive Phase 3 Attain‑Maintain results showing its oral GLP‑1 candidate, orforglipron, helped patients maintain weight after prior treatment with injectable GLP‑1 therapies....
Moderna secures CEPI backing: $54M to push H5 mRNA vaccine into Phase 3
Moderna won up to $54.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance its H5 avian influenza mRNA vaccine mRNA‑1018 into Phase 3 testing. The agreement follows...
FDA places partial hold: Daiichi‑Merck ADC program paused after excess deaths
The FDA imposed a partial hold on the global Phase 3 program for an antibody‑drug conjugate developed by Daiichi Sankyo and Merck following an unexpectedly high incidence of deaths that prompted a...
Harbour inks BMS antibody pact: $90M up front, $1B+ milestones possible
Harbour BioMed signed a discovery and development collaboration with Bristol Myers Squibb centered on next‑generation multispecific antibodies, with up to $90 million in upfront and early payments...
Personalis MRD assay predicts ICI response across solid tumors
A Phase I study published in Clinical Cancer Research showed Personalis’ NeXT Personal minimal residual disease (MRD) assay, a tumor‑informed whole‑genome sequencing liquid biopsy, accurately...
Machine learning remaps virus taxonomy: vConTACT3 enables scalable classification
Researchers introduced vConTACT3, a machine‑learning framework that enables scalable, hierarchical classification of eukaryotic and prokaryotic viruses across taxonomic ranks. Published in Nature...
Liver‑targeted mRNA rejuvenates aged T cells – boosts vaccines and immunotherapy
MIT researchers reported that transient liver delivery of mRNAs encoding key trophic factors (DLL1, FLT3L, IL‑7) restored naive and stem‑like T cell populations in aged mice, improving vaccine...
Orum raises $100M to develop degrader‑antibody cancer drugs
Orum Therapeutics closed a $100 million financing round to advance its pipeline of 'degrader‑antibody conjugates'—antibody vehicles that deliver protein‑degrading small molecules rather than...
Takeda’s TYK2 pick clears two phase 3s — approval push under way
Takeda announced that zasocitinib, the TYK2 inhibitor it acquired in a $4 billion deal, met primary and key secondary endpoints in two Phase 3 trials for plaque psoriasis. The company said the...
Lilly’s oral GLP‑1 holds weight after injectables — fast FDA review likely
Eli Lilly reported that its oral GLP‑1 candidate orforglipron met primary and key secondary endpoints in a Phase 3 maintenance trial, helping participants maintain weight lost on injectable GLP‑1...
CEPI injects $54.3M to keep Moderna’s H5 vaccine in phase 3
The Coalition for Epidemic Preparedness Innovations (CEPI) agreed to fund Moderna’s mRNA‑1018 H5 influenza vaccine with up to $54.3 million to advance the program into Phase 3. The deal follows US...
FDA places partial hold on Daiichi–Merck ADC after unexpected deaths
The FDA imposed a partial hold on Daiichi Sankyo and Merck’s global Phase 3 program for their investigational antibody‑drug conjugate (ADC) after companies paused enrollment citing a...
Peanut patch succeeds in pivotal trial — DBV to seek FDA approval
DBV Technologies reported positive top‑line results from the Vitesse Phase 3 trial: the Viaskin peanut epicutaneous patch met its primary endpoint in children aged 4–7, with a treatment responder...
GSK’s twice‑yearly biologic Exdensur wins FDA clearance
GSK gained FDA approval for depemokimab (Exdensur) as an add‑on maintenance therapy for severe eosinophilic asthma in patients aged 12 and older, becoming the first biologic cleared with...
Harbour BioMed seals $90M deal with Bristol Myers Squibb — $1B upside
Harbour BioMed signed a discovery and development collaboration with Bristol Myers Squibb to advance multispecific antibody therapeutics, securing approximately $90 million upfront and potential...
vConTACT3: machine learning remaps virus taxonomy at scale
Researchers published vConTACT3, a machine‑learning framework that enables multirank, large‑scale classification of eukaryotic and prokaryotic viruses, addressing taxonomic bottlenecks created by...
Liver‑targeted mRNA rebuilds aged immunity in mice — translational steps next
MIT researchers showed that transient hepatic delivery of mRNAs encoding DLL1, FLT3L and IL‑7 via LNPs restored naive and stem‑like T‑cell populations in aged mice, boosting vaccine responses and...
Insilico targets Hong Kong IPO to raise capital for AI drug pipeline — near $300M
AI‑drug developer Insilico Medicine filed for a Hong Kong IPO aiming to raise roughly HK$2.27 billion (about $292 million) to fund clinical development and expand investments in generative AI and...